809 related articles for article (PubMed ID: 24641480)
61. New insights into folliculotropic mycosis fungoides (FMF): A single-center experience.
Hodak E; Amitay-Laish I; Atzmony L; Prag-Naveh H; Yanichkin N; Barzilai A; Kershenovich R; Feinmesser M
J Am Acad Dermatol; 2016 Aug; 75(2):347-55. PubMed ID: 27245278
[TBL] [Abstract][Full Text] [Related]
62. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
Sentis HJ; Willemze R; Scheffer E
J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
[TBL] [Abstract][Full Text] [Related]
63. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
[TBL] [Abstract][Full Text] [Related]
64. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
65. Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy.
Klein RS; Dunlop JD; Samimi SS; Morrissey KA; Evans KG; Gardner JM; Introcaso CE; Vittorio CC; Rook AH; Micaily B; Kim EJ
J Am Acad Dermatol; 2013 Jun; 68(6):972-7. PubMed ID: 23415461
[TBL] [Abstract][Full Text] [Related]
66. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
Olsen E; Vonderheid E; Pimpinelli N; Willemze R; Kim Y; Knobler R; Zackheim H; Duvic M; Estrach T; Lamberg S; Wood G; Dummer R; Ranki A; Burg G; Heald P; Pittelkow M; Bernengo MG; Sterry W; Laroche L; Trautinger F; Whittaker S;
Blood; 2007 Sep; 110(6):1713-22. PubMed ID: 17540844
[TBL] [Abstract][Full Text] [Related]
67. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
68. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.
Moriarty B; Whittaker S
Expert Rev Hematol; 2015 Apr; 8(2):159-71. PubMed ID: 25495961
[TBL] [Abstract][Full Text] [Related]
69. Does the new staging system proposed for mycosis fungoides and Sézary syndrome provide reliable agreement for T1 and T2 disease?
Fernández-de-Misa R; Hernández Machín B; Aguirre-Jaime A; Pérez-Méndez LI; Peñate Y; Suárez Hernández J
Dermatology; 2015; 230(1):40-5. PubMed ID: 25471055
[TBL] [Abstract][Full Text] [Related]
70. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.
Toro JR; Stoll HL; Stomper PC; Oseroff AR
J Am Acad Dermatol; 1997 Jul; 37(1):58-67. PubMed ID: 9216524
[TBL] [Abstract][Full Text] [Related]
71. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
Dmitrovsky E; Matthews MJ; Bunn PA; Schechter GP; Makuch RW; Winkler CF; Eddy J; Sausville EA; Ihde DC
J Clin Oncol; 1987 Feb; 5(2):208-15. PubMed ID: 3492594
[TBL] [Abstract][Full Text] [Related]
72. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
73. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
74. Mycosis fungoides: classic disease and variant presentations.
Howard MS; Smoller BR
Semin Cutan Med Surg; 2000 Jun; 19(2):91-9. PubMed ID: 10892710
[TBL] [Abstract][Full Text] [Related]
75. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
Rampino M; Ragona R; Monetti U; Mussano A; Guarneri A; Sannazzari GL
Radiol Med; 2002; 103(1-2):108-14. PubMed ID: 11859306
[TBL] [Abstract][Full Text] [Related]
76. Survival prediction model for patients with mycosis fungoides/Sezary syndrome.
Zhu L; Han X; Liu Z; Leng S; Shan N; Lv X; Lu K; Hun S; Wu Y; Liu X
Future Oncol; 2020 Nov; 16(31):2487-2498. PubMed ID: 32746631
[No Abstract] [Full Text] [Related]
77. Mycosis fungoides.
Zinzani PL; Ferreri AJ; Cerroni L
Crit Rev Oncol Hematol; 2008 Feb; 65(2):172-82. PubMed ID: 17950613
[TBL] [Abstract][Full Text] [Related]
78. [Prognosis of primary cutaneous lymphomas].
Grange F; Bagot M
Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):30-40. PubMed ID: 11937927
[TBL] [Abstract][Full Text] [Related]
79. Risk of progression of early-stage mycosis fungoides, 10-year experience.
Ariza Gómez SA; Dubeibe Abril PA; Niebles Sincelejo OE; Reina HSL
An Bras Dermatol; 2024; 99(3):407-413. PubMed ID: 38395632
[TBL] [Abstract][Full Text] [Related]
80. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
Meissner K; Löning T; Rehpenning W
Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
